[The good, the bad, the ugly] Editor's Review week of March 25

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — FDA approves Akebia Therapeutics' Vafseo anemia drug
The bad — Bristol Myers Squibb's Crohn's disease drug disappoints
The ugly — FDA rejects Regeneron Pharmaceuticals lymphoma treatment